Neuphoria Therapeutics Inc., a clinical-stage biopharmaceutical company, has been making significant strides in the healthcare sector, particularly in the development of novel allosteric ion channel modulators aimed at treating central nervous system disorders. Based in Burlington, Massachusetts, and formerly known as Bionomics Limited, the company has undergone a strategic rebranding in December 2024 to better reflect its innovative focus and therapeutic ambitions.
As of July 21, 2026, Neuphoria Therapeutics Inc. is listed on the Nasdaq with a close price of $3.33, reflecting a notable fluctuation from its 52-week high of $21.4 on October 6, 2025, to a low of $3.19 on June 30, 2026. Despite these market variations, the company maintains a market capitalization of approximately $17.8 million, underscoring its potential in the biopharmaceutical landscape.
Central to Neuphoria’s pipeline is BNC210, a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, currently in phase 2b clinical trials for the treatment of post-traumatic stress disorder (PTSD). This candidate also holds promise for addressing social anxiety disorder, marking a significant advancement in therapeutic options for these conditions.
In addition to BNC210, Neuphoria is advancing BNC101, a monoclonal antibody that has successfully completed phase 1 clinical trials. This candidate targets cancer stem cells, positioning it as a potential breakthrough in oncology. Concurrently, BNC105 is being developed for cancer treatment, further expanding the company’s oncological portfolio.
Neuphoria’s innovative pipeline extends to NextGen, a preclinical trial candidate aimed at treating multiple central nervous system indications. Additionally, the company is exploring a Kv3.1/3.2 agonist in preclinical trials, targeting cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders.
A pivotal collaboration with Merck & Co., Inc. underscores Neuphoria’s strategic partnerships, focusing on the development of α7 receptor positive allosteric modulators. This collaboration targets cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions, highlighting Neuphoria’s commitment to addressing unmet medical needs.
Since its incorporation in 1996, Neuphoria Therapeutics Inc. has demonstrated a steadfast commitment to innovation and therapeutic development. With a robust pipeline and strategic collaborations, the company is well-positioned to make significant contributions to the treatment of central nervous system disorders and cancer, promising a brighter future for patients worldwide.
